LEO LUZNIK to Risk Assessment
This is a "connection" page, showing publications LEO LUZNIK has written about Risk Assessment.
Connection Strength
0.041
-
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2017 Apr; 23(4):612-617.
Score: 0.015
-
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
Score: 0.013
-
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
Score: 0.013